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Abstract
Background: In our previous studies, we reported positive associations between seven ADH4
polymorphisms and substance dependence [i.e., alcohol dependence (AD) and/or drug dependence
(DD)] in European-Americans (EAs). In the present study, we address the relationship between
ADH4 variation and substance dependence in an African-American (AA) population, and report
evidence that supports an association between a different ADH4 polymorphism (rs2226896) and
these phenotypes in AAs.
Methods: Two family-based association study methods, i.e., TDT and FBAT, were applied to test
the relationship between ADH4 variation and substance dependence in Sample 3 (112 small nuclear
families) and in Sample 4 (632 pedigrees), respectively. A population-based case-control association
study method was also applied to test this relationship in 1303 unrelated subjects, with and without
controlling for admixture effects. Finally, a Hardy-Weinberg Disequilibrium (HWD) test was
applied to examine the association in the case-only sample, infer the genetic disease models, and
distinguish the disease and non-disease factors contributing to HWD.
Results: The marker examined was found to be in significant HWD in AA alcoholics (p = 0.0071)
and drug dependent subjects (p = 0.0341), but in Hardy-Weinberg Equilibrium (HWE) in all other
subgroups. Other association methods failed to detect any association between this variation and
phenotypes. The best-fit genetic disease model for this marker is a recessive genetic model.
Conclusion: ADH4 variation might play a role in risk for substance dependence in AAs, potentially
via a recessive mechanism. Under certain conditions, the HWD test could be a more powerful
association method than conventional family-based and population-based case-control association
analyses, for which, the present study provides an extreme example.
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The rate of alcohol metabolism influences drinking
behavior and affects risk for alcohol dependence (AD).
The alcohol dehydrogenases (ADH) and the aldehyde
dehydrogenases (ALDH) are the two major categories of
alcohol-metabolizing enzymes in the liver. ADH converts
alcohol to acetaldehyde (which is toxic) and then ALDH
converts acetaldehyde into acetate. Acetate is then oxi-
dized into CO2 and H2O via the tricarboxylic acid cycle.
The development of AD is related to an individual's level
of ethanol consumption, which is influenced by ADH and
ALDH activity. The human ADH4 enzyme (i.e., π subunit)
is an important member among these alcohol-metaboliz-
ing enzymes. It mainly contributes to liver ADH activity,
and at intoxicating levels of alcohol it may account for as
much as 40% of the total ethanol oxidation rate [1]. Thus,
physiologically significant variation in ADH4 activity
could clearly contribute to variability in risk for AD.
The human ADH4 enzyme is encoded by the ADH4 gene,
which maps to 4q22 within the ADH gene cluster. We
focused on the ADH4 gene in this study because of the
functional importance of its protein product, remarkable
for its activity at high ethanol concentrations that might
be of particular relevance in the context of AD risk [2]; and
because previous studies have demonstrated that ADH4 is
an important risk gene for AD and AD-related traits in
European-Americans (EAs) and African-Americans (AAs).
Guindalini et al. [3] reported that the ADH4 promoter var-
iants -75A/C (rs1800759), which can significantly alter
the expression of the ADH4 enzyme [4], and -159A/G,
were significantly associated with AD in EAs and AAs in a
Brazilian population. Edenberg et al. [5] reported that six-
teen ADH4 polymorphisms (including rs2226896) were
associated with AD in an independent Collaborative
Study on the Genetics of Alcoholism (COGA) sample of
pedigrees. We have previously reported associations
between seven ADH4 polymorphisms (including -75A/C)
and AD and drug dependence (DD) in EAs in the US pop-
ulation [6,7]. We also reported that three ADH4 polymor-
phisms (including -75A/C) were associated with
personality traits in AD and DD subjects [8].
In our previous studies [6,7], we genotyped seven mark-
ers in some of the subjects included in the present study.
These seven markers span the full length of ADH4 and
are in one haplotype block both in EAs and AAs. The
seven ADH4 markers showed deviation from Hardy-
Weinberg Equilibrium (HWE) (called Hardy-Weinberg
Disequilibrium, HWD) in EA substance dependent sub-
jects (including patients with AD and DD), but were in
HWE in EA healthy controls. Significant differences in
genotype and diplotype, but not in any allele or haplo-
type, frequency distributions for all seven ADH4 markers
were found between cases and controls in EAs (adjusted
global p = 0.0070, 0.0004 for AD and DD, respectively).
We also demonstrated that ADH4 genotypes predispose
to AD and DD consistent with a recessive mode of inher-
itance in EAs. These associations remained after control-
ling for admixture effects and were confirmed by a
family-based association study. However, in AAs, these
seven ADH4 markers were in HWE in both cases and
controls; no association between alleles, genotypes, hap-
lotypes, or diplotypes of these markers and AD and DD
were found in this population, even after controlling for
admixture effects.
Although we did not find a significant association
between these seven ADH4 variants and AD or DD in AAs
in our previous studies, in view of the power variance of
association methods and the population-specificity of
associations, we did not exclude the possibility that these
associations might be significant if adequate statistical
power were available, or that other markers might be asso-
ciated with these phenotypes in this population [6,7]. The
present study aimed to identify an association between a
specific polymorphism, rs2226896 (for convenience and
to distinguish it from the seven polymorphisms on which
we reported previously, we refer to this variant as SNP8)
and AD, in AAs. This polymorphism has a rare allele and
a rare homozygote which could result in its being inde-
pendent of the flanking haplotype block and could
increase the relative risk between genotypes so that it
could be a more powerful marker for some specific asso-
ciation analysis methods (e.g., the HWD test) to detect
marker-phenotype association [9]. To test the population-
specificity of this association, we also tested for it in EAs,
the most common population in the US.
As different association methods have different advan-
tages, disadvantages, and power associated with them, in
the present study, we applied several methods and com-
pared their power. Family-based association study meth-
ods are immune to population stratification and
admixture effects, and (as generally applied) are not
informed by the affection status of parents. This method
has been used as a valid confirmatory method for a popu-
lation-based association study in our previous study [6]
and was applied in the present study as well. However,
because the sample size of families is usually limited, and
families usually provide around two-thirds of the power
provided by unrelated case-control samples of similar size
[10], we also performed a case-control association study.
AAs are an admixed population, and EAs are admixed as
well, although much less so [11-14]. Admixture effects
may result in spurious observed association between gene
and disease. A population-based case-control association
study is vulnerable to these effects. Therefore, the degree
of admixture was also measured in the case-control sam-
ple, and admixture effects on the case-control association
analysis were controlled by a structured association (SA)
method [15].Page 2 of 13
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was more powerful (with lower p values) than a case-con-
trol association analysis under a recessive model [7]. The
present study provided an additional application for this
powerful association method. Meanwhile, we used an
HWD test to infer the genetic disease model, via a set of
novel software programs developed by Wittke-Thompson
et al. [9], which incorporate the HWD information from
both cases and controls. HWE is subject to a number of
assumptions regarding genotyping error, selection,
genetic drift, inbreeding, gene flow, and mutation, and to
other factors such as population stratification, admixture,
nonrandom patterns of missing data, and nonrandom
allele dropout with increasing age. HWD may be caused
by the violation of any one of these assumptions; thus, we
also distinguished the underlying causes for HWD by the
above methodology via application of the recently-devel-
oped programs and by reviewing almost all possibility for
the causes of HWD in details.
Drug dependence (DD), which mainly includes cocaine
dependence and opioid dependence in our sample, is one
of the most common phenotypes comorbid with AD [16].
DD has many features in common with AD, including
symptomatology, neuropsychological impairment,
hypothesized pathogenetic mechanisms, and response to
specific treatments (reviewed by Luo et al [7]). DD has
also been reported to share some susceptibility genes with
AD (reviewed by Luo et al [6,7,17]). Our previous study
demonstrated that DD and AD share ADH4 as a suscepti-
bility gene in EAs [6,7]. Thus, in this study, we investi-
gated the association not only in AD, but also in DD, to




The clinical samples are listed in Tables 1 and 2, including
Sample 1 (907 unrelated case-control subjects), Sample 3
(112 small nuclear families (SNFs); each family includes
parents and 1 to 2 offspring) [both samples were used in
previous studies by Luo et al [6,7]], Sample 2 (271 newly
recruited unrelated AA cases and 125 unrelated AA con-
trols), and Sample 4 (1613 related subjects from 632 ped-
igrees; each pedigree has 1 to 6 affected siblings with or
without parents) [Sample 4 was previously described by
Gelernter et al [18,19]]. Samples 1 and 2 included a total
of 1303 unrelated subjects (757 males and 546 females),
with 391 "genetic" EA cases, 310 "genetic" EA healthy
controls (European ancestry proportion > 0.5), 429
"genetic" AA cases, and 173 "genetic" AA controls (African
ancestry proportion > 0.5; see Methods). Newly-recruited
subjects (Sample 2) were diagnosed using the Semi-Struc-
tured Assessment for Drug Dependence and Alcoholism
(SSADDA) [18,20]. The healthy control subjects (in Sam-
ples 1 and 2) were screened to exclude major Axis I mental
disorders, including alcohol or drug use disorders, psy-
chotic disorders (including schizophrenia or schizophre-
nia-like disorders), mood disorders, and major anxiety
disorders. Sample 4 included pedigrees having affected
probands with substance dependence, previously used for
genome-wide linkage studies [18,19]. Diagnosis was
made according to DSM-III-R or DSM-IV criteria [21,22].
Samples 1, 2 and 3 were recruited at the University of
Connecticut Health Center, the VA Connecticut Health-
care System-West Haven Campus, or the Medical Univer-
sity of South Carolina. Sample 4 was recruited at four
sites: University of Connecticut Health Center (Farming-
Table 1: Sample size for the unrelated sample and the related small nuclear families.
Sample sizes
%Male Age (years) EA AA Hispanic Others
Sample 1 Healthy controls 39.9 28.2 ± 9.1 310 48
Cases 73.4 39.4 ± 9.2 391 158
AD 76.1 40.3 ± 9.2 326 101
DD 68.2 37.1 ± 8.1 204 145
Sample 2 Healthy controls 28.0 33.5 ± 12.6 125
Cases 64.9 40.0 ± 9.3 271
AD 65.1 40.0 ± 9.3 269
DD 64.8 42.0 ± 8.3 71
Sample 3 SNF size 92 12 6 2
Parents 49.8 65.9 ± 8.6 183 24 11 3
%Unaffected 45.5 66.8 ± 8.6 79.8 37.5 63.6 100.0
Offspring 54.8 39.2 ± 11.1 96 13 5 1
AD 58.9 37.3 ± 8.2 77 9 3 1
DD 55.2 38.0 ± 7.3 77 13 5 1
EA, European-American; AA, African-American; AD, alcohol dependence; DD, drug dependence; SNF, small nuclear families. Samples 1 and 2 are 
unrelated case-control samples; Sample 3 is related SNF sample.Page 3 of 13
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CT), McLean Hospital, Harvard Medical School (Belmont,
MA), and Medical University of South Carolina (Charles-
ton, SC). All subjects gave informed consent before partic-
ipating in the study, which was approved by the
Institutional Review Board at the respective institutions.
2. Genotyping
A marker (rs2226896; SNP8; at Chr04: 100460117) at the
putative 5' regulatory region, close to the functional vari-
ant -75A/C (at Chr04: 100458289; 1.8 Kb to 3' of SNP8)
at the promoter and other disease-related polymorphisms
at this region (e.g., -159G/A at Chr04: 100458373, 1.7 Kb
to 3' of SNP8 [3]; rs1984362 at Chr04: 100463753, 3.6 Kb
to 5' of SNP8 [6,7]) was genotyped in all subjects using
the TaqMan technique ("assay-on-demand"). These eight
ADH4 SNPs were all of those that were available from
public sources when we started genotyping. SNP8 was not
reported together with other seven SNPs in our previous
studies [6,7] because it was not associated with any phe-
notype in EAs. The detailed genotyping procedure is
described elsewhere [7]. All genotyping was performed in
duplicate and compared to ensure validity of the data.
Mismatched genotypes, if any, were discarded. Thirty-
eight unlinked ancestry-informative markers (AIMs) were
also genotyped in unrelated subjects to estimate the
ancestry proportions for each subject (detailed by Luo et
al [6]).
3. Statistical analysis
1) Linkage disequilibrium (LD) analysis: Pairwise LD
between this marker and the other seven ADH4 markers
studied previously was analyzed separately for EAs and
AAs in Sample 1 via the program Haploview [23]. The
additional newly recruited 271 AA unrelated cases and
125 unrelated AA controls (Sample 2), and the related
pedigree subjects (Sample 4) were not included in this
analysis because the other flanking seven ADH4 markers
have not been genotyped in these subjects.
2) Transmission disequilibrium test (TDT): Family-based
association analysis was performed by comparing "cases"
(i.e., transmitted allele and genotypes) and artificial "con-
trols" (i.e., untransmitted allele and genotypes) in Sample
3 by the program TDTPHASE [24]. All subjects in Sample
3, including EA, AA, Hispanic, and others, and the affected
and unaffected parents, were combined in the TDT analy-
sis. This analysis was also performed separately within EAs
and AAs.
3) Family-Based Association Tests (FBAT): The structure of
Sample 4 is much more complicated than Sample 3, thus,
we used the program FBAT [25] to test the gene-AD and
gene-DD associations under the general, additive, domi-
nant, and recessive genetic models respectively. We have
already genotyped 419 short tandem repeats (STRs) in
this sample in the initial whole genome scan linkage stud-
ies [18,19], and inferred the ancestry proportions in each
individual. The whole sample can thus be separated into
"genetic" EAs (European ancestry proportion > 0.5) and
"genetic" AAs (African ancestry proportion > 0.5), accord-
ing to the ancestry proportions in probands. FBAT was
performed in the whole sample including EAs, AAs, His-
panics, and others. This analysis was also performed sep-
arately within "genetic" EAs and AAs, because the
population-specificity of the gene-disease linkage and the
disease-risk sites has ever been demonstrated in this sam-
ple [18,19].
4) Case-control comparisons for allele and genotype fre-
quencies: Allele and genotype frequencies for SNP8
among EAs and AAs in Samples 1 and 2 are shown in
additional file 1. Associations between alleles, genotypes
and phenotypes were tested by comparing the allele and
genotype frequency distributions between cases and con-
trols with the exact tests in the program PowerMarker
[26].
5) Structured association (SA) analysis: EAs and AAs were
taken as admixed populations with different degrees of
admixture. The extent of admixture (i.e., average ancestry
proportions) in unrelated subjects was estimated using
the program STRUCTURE [15] by analyzing 38 AIMs (in
combined EA and AA subjects) [6,27,28]. Admixture
effects on case-control association analysis can be control-
led using the program STRAT [29] by conditioning the
analysis on the ancestry proportions, i.e., structured asso-
ciation (SA) analysis (separately for EAs and AAs). Fur-
thermore, associations between this ADH4 variation and
phenotypes were also analyzed by a regression method
Table 2: Structure and sizes of pedigrees (Sample 4)
Total EAs AAs Others
Subjects 1613 766 833 14
%Male 46.3 51.4 41.2 71.4
Age (year) 39.4 ± 8.9 37.8 ± 10.2 40.8 ± 7.2 43.7 ± 5.7
Pedigrees 632 311 316 5
With 1 AD 242 115 126 1
With 2 AD 166 87 78 1
With 3 AD 11 5 6 0
With 4 AD 5 2 3 0
With ≥ 5 AD 1 0 1 0
With 1 DD 57 25 32 0
With 2 DD 460 243 216 1
With 3 DD 90 35 55 0
With 4 DD 16 7 9 0
With ≥ 5 DD 3 0 3 0
EA, AA, AD, DD, same as Table 1. "With n AD", a pedigree having n 
offspring with AD; as analogy.Page 4 of 13
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age, and sex serving as covariates.
6) Hardy-Weinberg equilibrium (HWE) test and genetic
disease model inference: An HWE test can be a valid asso-
ciation method, and can be used to infer genetic disease
models. HWE was tested within populations, and sepa-
rately for cases and controls, using the goodness-of-fit χ2
test implemented in the program PowerMarker [26]. If
there was one cell with expected genotype count less than
5, HWE was also tested by the exact test implemented in
the program PowerMarker [26] and confirmed by the
exact test implemented in the online program FINETTI
[30], and the exact tests implemented in the program
TFPGA [31] which applies conventional Monte Carlo and
Markov Chain Monte Carlo (MCMC) methods.
To distinguish the causes of HWD, which include gene-
disease association and non gene-disease association fac-
tors such as genetic drift, migration, mutation, non-ran-
dom mating, etc., and then to infer the genetic disease
model for the marker in HWD, we used the goodness-of-
fit χ2 test defined by Wittke-Thompson et al. [9], which
incorporated the HWE information both from cases and
controls (here denoted WT goodness-of-fit χ2 test) [9]. The
test statistic  (i, j = 1, 2
or 3), where Oi and Ei are the observed and expected num-
bers of ith genotype of this marker in patients, respectively;
Oj and Ej are the observed and expected numbers of jth gen-
otype of this marker in controls, respectively. Assuming
different baseline penetrance of disease (from 0 to 1) for
non-susceptibility homozygotes, different heterozygote
relative risk, and different susceptibility homozygote rela-
tive risk that determine different Ei and Ej given different
genetic models, and setting the lifetime population prev-
alence of alcohol dependence and drug dependence at
5.5% and 3.8% [32], respectively, we can obtain a differ-
ent set of χ2 values. Minimizing this χ2 statistic over the
entire parameter space with the appropriate constraints
on the parameters approximates a maximum-likelihood
estimate procedure. We can then obtain the minimal (χ2)0
value, which is approximately distributed as a χ2 with 1 df
for a general model and 2 df for restricted models (i.e.,
dominant, recessive, additive, and multiplicative models)
[33]. Simulating 173 AA controls and 370 AA AD subjects
or 216 AA DD subjects for 1000 replications to obtain
1000 minimal χ2 values and comparing these values to
the original minimal (χ2)0 value, we can derive an empiric
p-value. If this p-value is less than 0.05, the genetic disease
model can be rejected as a poor fit to the observed data.
The best-fit genetic model would correspond to a p-value
which is larger than 0.05 and is the largest among all
genetic models. If all of the genetic models are poorly fit-
ted, then alternative explanations for the HWD, including
chance, genotyping error, and/or violations of the requi-
site assumptions of HWE, must be considered.
The direction of HWD statistics (Δ, F and J values, detailed
definitions follow) in cases is also helpful to judge the
genetic models. Under the dominant and the additive
models, the values of Δ, F and J are negative, because
HWD is caused by an excess of observed heterozygote
(Aa) and homozygote (AA) frequencies over the expected
frequencies. Under the recessive model, the values of Δ, F
and J are positive, because the HWD is caused by excess of
observed homozygote (aa) frequency over the expected
frequency, and in contrast, observed heterozygote (Aa)
frequency is less than expected. These statistics were calcu-
lated based on the following formula: Assuming that fo',
fo", fo"', and fe', fe", fe"' denote the observed and expected
frequencies of susceptibility homozygote, heterozygote
and non-susceptibility homozygote in cases, respectively,
then Δ = fo'''-fe''', F = 2Δ/fe'' and J = Δ/fe"' [34-36].
Results
1. SNP8 was in LD with the seven flanking markers in EAs
(D' > 0.9 in each case), but provided information inde-
pendent of these markers in AAs (D' < 0.10 in each case)
(Figure 1). TDT in Sample 3 and FBAT in Sample 4
showed no significant association between the ADH4
SNP8 and AD or DD, whether analysis is conducted by
combining or separating the different ethnicities (all p >
0.05) (Sample 3: see additional file 2; Sample 4: data not
shown). The genotype frequency distributions in Sample
4 were shown in Table 3, not for the association analysis,
but for providing a replication of the rare genotype fre-
quencies to those in the unrelated Samples 1 and 2 (see
additional file 1).
2. SNP8 was not associated with phenotypes via case-con-
trol comparisons either before or after controlling for
admixture effects. Measured admixture degrees were low
both in EAs and AAs.
No significant difference in allele or genotype frequency
distribution for this marker was found between unrelated
cases and controls in either EAs or AAs (all p > 0.05; addi-
tional file 1). After controlling for admixture effects by the
SA method, these negative associations were essentially
unchanged (all p > 0.05). Regression analysis, which takes





−( )∑ ∑Oi EiEi
O j E j
E ji jPage 5 of 13
(page number not for citation purposes)
Behavioral and Brain Functions 2008, 4:42 http://www.behavioralandbrainfunctions.com/content/4/1/42Two main ancestries, i.e., European and African, were
detected in our sample. In the 701 "genetic" EA subjects
(European ancestry proportion > 0.5), the total estimated
weight of African ancestry proportions is 11.3; the admix-
ture degree of "genetic" EAs in this sample is 1.6% (=
11.3/701). In the 602 "genetic" AA subjects (African
ancestry proportion > 0.5), the total estimated weight of
European ancestry proportions is 23.7; the admixture
degree of "genetic" AAs is 3.9% (= 23.7/602).
3. SNP8 was in significant HWD in both AA AD and DD
subjects (with an excess of observed homozygotes over
expected homozygotes): using the exact tests: p = 0.0071
for AD and p = 0.0341 for DD, respectively. These HWDs
remained significant or suggestive after correction for
multiple testing (α was set at 0.025). However, SNP8 was
in HWE in EA AD and DD subjects (p > 0.05) (additional
file 1). This marker was in HWE in controls, both EA and
AA (p > 0.10). The WT goodness-of-fit χ2 test showed that
the best-fit genetic disease model for this marker was a
recessive model (in AA AD subjects: χ2 = 0.621, df = 2, p =
0.733; in AA DD subjects: χ2 = 1.596, df = 2, p = 0.450; see
additional file 1). In AA AD subjects for this marker, Δ =
+0.008, F = +0.182 and J = +0.009; in AAs with drug
dependence, Δ = +0.008, F = +0.204 and J = +0.010.
Discussion
In African-Americans (AAs), the SNP8 G/G genotype was
never observed in any of the control subjects in Sample 1
(n = 48), the newly-recruited unrelated controls in Sample
2 (n = 125), or the additional related unaffected pedigree
subjects (n = 128; see Table 3) (i.e., in total there were 0/
301 observations); this genotype was, however, observed
in unrelated cases (e.g. 4/370, for AD). We cannot com-
pletely exclude the possibility that the difference between
cases and controls is attributable to sampling bias and the
findings are false positive, but we conjecture that it is
more likely that this genotype is related to phenotype in
AAs, although there is not enough information in this
observation alone to support such a conclusion. Because
this genotype is so rare (1%), some association methods
with insufficient power might not detect a true genotype-
phenotype association (in fact, evaluated by exact test as a
case-control genotype frequency distribution comparison,
this comparison shows p = 0.391 and 0.225 for AD vs.
controls and DD vs. controls, respectively). Thus, in the
present study, several association methods with differing
power and that take different views of the data were
applied and compared. The most powerful HWD test sug-
gests that the ADH4 variant (rs2226896) might play an
important role in risk for substance dependence (includ-
ing AD and DD) in AAs, probably via a recessive genetic
mechanism. The association between this variant and
phenotype is population-specific, that is, it appears in
AAs, but not in EAs. This association herein first discov-
ered in AAs is a complementary finding to a previous set
of genotype-phenotype relations we described for other
markers at this locus in EAs [6,7]; based on this result, we
can now provisionally conclude that ADH4 affects SD risk
in both EAs and AAs, but different variants are important
in the different populations. It would be of great interest
to study this variant in other populations, e.g., Asians, to
further characterize the population specificity we report
here. This variant is independent of the other seven poly-
morphisms that were reported previously to have no asso-
ciation with substance dependence in AAs [6,7].
ADH4 gene variation is thought to influence the risk for
AD by modulating ethanol metabolism. However, we find
that it is associated with DD too. This is reasonable
because DD has many features in common with AD
which are reviewed above and because the development
of AD and DD might have some similar pathophysiologi-
cal mechanisms. ADH4 enzyme (π ADH) catalyzes syn-
thesis from substrates (which include, e.g.,
norepinephrine aldehydes, including 3,4-dihydroxyman-
delaldehyde (DHMAL) and 4-hydroxy-3-methoxymande-
laldehyde (HMMAL)) to create the intermediary glycols of
norepinephrine metabolism, including 3,4-dihydroxy-
phenylglycol (DHPG) and 4-hydroxy-3-methoxyphenylg-
lycol (HMPG), respectively. This catalysis is considerably
more efficient via this isozyme than for any of the class I
Table 3: Genotype frequency distributions of SNP8 in pedigrees (Sample 4)
European-American African-American
AD DD Unaffected AD DD Unaffected
N f N f N f N f N f N f
A/A 271 0.903 541 0.905 85 0.895 293 0.945 626 0.963 127 0.992
A/G 26 0.087 53 0.089 8 0.084 16 0.052 24 0.037 1 0.008
G/G 3 0.010 4 0.007 2 0.021 1 0.003 0 0.000 0 0.000
A 568 0.947 1135 0.949 178 0.937 602 0.971 1276 0.982 255 0.996
G 32 0.053 61 0.051 12 0.063 18 0.029 24 0.018 1 0.004
AD, alcohol dependence; DD, drug dependence.Page 6 of 13
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does not have any detectable catalytic activity towards
these substrates at all [37]. Increased π ADH activity – e.g.,
through genetic variation, such as, potentially, the SNP8
G/G genotype – could lead to increasing levels of DHPG
and HMPG, and a very high turnover of norepinephrine
aldehydes. To block the turnover of norepinephrine alde-
hydes, perhaps one might self-administer ethanol to com-
pete DHPG and HMPG, because ethanol is an external
competitor for internal DHPG and HMPG on π ADH [37].
This mechanism could lead to AD. Cocaine, which par-
tially functions as a norepinephrine re-uptake inhibitor,
Pairwise LD between the candidate marker SNP8 and other seven flanking markers in unrelated African-American subjectsFigure 1
Pairwise LD between the candidate marker SNP8 and other seven flanking markers in unrelated African-
American subjects. [D' = 1.00 in the blank squares; the numbers inside the red squares are D' × 100%; the blue squares rep-
resent low r2 values; the white squares represent low D' and low r2 values. SNPs 1–7 were reported previously in Luo et al. 
(2006) and span from 3' to 5'.].Page 7 of 13
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phrine and norepinephrine concentrations were signifi-
cantly increased in response to cocaine injection [38].
Intravenous opioids stimulate norepinephrine and acetyl-
choline release in cerebrospinal fluid [39]. Therefore, self-
administration of drugs (cocaine and opiates) could ele-
vate norepinephrine aldehydes too, which may lead to
DD.
A family-based association study is immune from popula-
tion stratification effects. Thus, in the present study, sub-
jects with different ethnicities, including EA, AA,
Hispanic, and others, and the affected and unaffected par-
ents, were combined in the analysis, to increase the statis-
tical power. Allowing for the possible population-
specificity of association, we also performed this analysis
separately within EAs and AAs. However, the family-based
association studies revealed no significant association
between this ADH4 variation and substance dependence
(both in Samples 3 and 4). This is likely due to the limited
statistical power, given the small sample size (Sample 3:
115 affected offspring and 221 parents), in the context of
the fact that the SNP8 variant has a rare minor allele (Sam-
ple 3: frequency ≤ 0.049 in AAs and ≤ 0.077 in EAs; Sam-
ple 4: frequency ≤ 0.020 in AAs and ≤ 0.053 in EAs;).
Additionally, only heterozygous parents yield TDT infor-
mation, which further limits the power for the family-
based association studies.
In the present study, our case-control sample (820 cases;
483 controls) has approximately five times the power of
the family Sample 3 [10]. However, neither allelewise nor
genotypewise case-control comparisons showed any sig-
nificant association between ADH4 variation and sub-
stance dependence. The case-control design is
theoretically vulnerable to population stratification that
could result in false negative findings. We therefore used
the structured association (SA) method [15] to exclude
population stratification and admixture effects on associ-
ations. The results did not change substantively after con-
trolling for population stratification and admixture
effects, i.e., both were negative. Similarly, despite taking
into account the potential confounding effects of age and
sex via regression analysis, no association between this
variation and phenotypes was detected. Additionally, the
low detected admixture degrees in EAs (1.6%) and AAs
(3.9%) (which may have appeared especially low, partic-
ularly in the AAs, because of lack of inclusion of an ances-
tral African population) suggest that admixture effects
should not have substantially affected the analysis in this
study. It is possible that the negative findings from the
case-control association might, like the TDT analysis and
the FBAT analysis, result from insufficient power.
For this particular marker, the allele frequency of the rare
allele is higher for EAs than for AAs (0.077 vs. 0.046, for
the control subjects). EAs are therefore expected to have a
substantially higher frequency of rare homozygotes than
AAs – 0.006 vs. 0.002, i.e. about three times as many.
Therefore, we specifically considered possible European
admixture in the four homozygous AA patients. We found
that the European ancestry proportions in these four AA
subjects were less than 0.72%, indicating these observa-
tions of the rare homozygote are unlikely to be related to
the genomewide European admixture in these AA sub-
jects.
HWD at SNP loci in the case sample could be an indicator
of gene-phenotype association [7,9,35-42]. Cases are
ascertained due to their "affected" status, so disease sus-
ceptibility genotypes or alleles should be present at high
rates in the case sample, which might violate HWE. Fur-
ther, because cases are not randomly sampled from the
general population where there is random mating and 2N
alleles among N subjects are independent, HWE of dis-
ease-related marker loci in cases could be violated, and 2N
alleles could become dependent. Only when the marker
has no LD with the disease locus, i.e., the marker genotype
frequency distributions are independent of the diagnosis,
can the case group and the control group have the same
genotype frequency distributions, with both in HWE.
Therefore, the HWD of SNP8 in AD and DD among AAs
in the present study suggests an association between SNP8
and both AD and DD. Usually, susceptibility loci are in
HWD in cases, but in HWE in controls [7], as observed for
SNP8. This is because a much greater sample size is
needed to detect HWD in controls than in cases [9]. If the
predisposing effect of the disease susceptibility allele is
strong enough and the sample size for controls is large
enough, this locus could also be in HWD in controls, but
with an excess of the protective genotype, the opposite of
the situation for cases [9]. SNP8 does not, apparently,
have a strong enough effect on risk to distort HWE in con-
trols; alternatively, the size of the control sample is not
large enough to detect HWD in that sample.
Additionally, substance dependence significantly
increases mortality [43-45], leading to age cohort-related
dropout of the disease-associated genotypes or alleles
from the population (i.e., natural selection). Selection by
mortality may violate an assumption for HWE and cause
altered distribution of genotype frequencies (i.e., HWD)
[46]. This dropout makes the risk genotype or allele rarer,
but the risk genotype or allele is still more common in
cases than in controls, consistent with what we observed
for SNP8, and providing additional evidence that SNP8
might be a disease-associated locus.Page 8 of 13
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distance between the marker loci and the disease locus;
that is, deviations from HWE are greatest at trait suscepti-
bility loci, and can also be detected for benign polymor-
phisms that are in LD with the susceptibility locus
[35,40]. In the present study, SNP8 is in HWD in cases,
which suggests that the risk locus for substance depend-
ence might be located in the SNP8-containing haplotype
block or be SNP8 itself.
The association evident from the HWD test was not
detected by case-control frequency comparison. This is
because the HWD test as an association method is, some-
times, much more powerful than case-control compari-
son [7], for which, the present study provides an extreme
example. One reason is that, from a statistical perspective,
the HWD test in cases has one degree of freedom (df = 1),
rather than df = 2 for case-control genotype frequency
comparisons. Another reason for greater power of the
HWD test in the present study is the age difference
between cases and controls, from an epidemiological
viewpoint, as discussed in our previous study [7]. In this
study, the average age for controls was 29.7 years, about
10 years younger than that for cases, 39.6 years. Many
healthy controls, although presently unaffected, have not
completely passed through the age of risk to manifest AD
or DD. The healthy controls have a probability (≈ lifetime
prevalence of disease; less than the cumulative prevalence
by the subject's age) to develop disease at some point in
the future, and this probability increases with the residual
prevalence, so that the case-control association design
may be less powerful than a case-only study using the
HWD test. That is, some associations that can be discov-
ered by the use of a case-only study might not be detected
using a case-control design. Meanwhile, because the drop-
out of disease-related genotypes or alleles increases with
the age of cases (due to increasing mortality), an HWD
test that reflects the dropout could be more sensitive to
detect this disease-related locus, especially when cases are
much older than controls.
The HWD signal of a marker locus decays more rapidly
with distance from a causative locus than the LD signal
[35]. The closer a marker is to the causative locus, the
greater the excess of power for the HWD test over the LD
test. Nielsen et al. [40] demonstrated that the HWD
method was more powerful than the LD method under
certain conditions (recessive and additive models), which
was also supported by many other studies [7,9,35,47-49].
Kocsis et al. [50] demonstrated that even in the absence of
significant differences in genotype frequency distribution
between cases and controls, associations can be detected
by HWD, as observed for SNP8 in present study. This is
particularly true for a trait-associated marker that acts via
a recessive mode of inheritance, because the effect of the
recessive allele (i.e., the disease-risk allele) can be
"masked" by the dominant allele (i.e., the non-disease-
risk allele), which yields negative results in case-control
frequency comparisons [under HWD, the two alleles are
dependent and affect each other]. From the formula of
goodness-of-fit χ2 test for HWD, the χ2 value (HWD statis-
tic) is proportional to the sample size (N) and the squared
difference between observed genotype frequency and the
expected frequency (Δ2), and inversely proportional to the
expected genotype frequencies. Thus, even when the Δ is
small, one rare genotype frequency could generate a high
HWD statistic. If the expected count of this rare genotype
is less than 5, we use an exact test; the exact p value is usu-
ally consistent with that from the goodness-of-fit χ2 test,
as seen in additional file 1. This is why HWD test is espe-
cially sensitive to a marker with one rare genotype.
HWD might not be more powerful than LD method in
detecting gene-disease association when a trait-associated
marker acts via a multiplicative mode of inheritance,
because HWD test would have very little power under this
disease model [35,40,41,47-49,51]. However, SNP8
unlikely acts via a multiplicative model in the present
study (p ≤ 0.007, see additional file 1). A new method, the
weighted average (WA) statistic test, has been reported to
be even more powerful than the HWD test to detect asso-
ciation between disease susceptibility and marker loci
under many genetic inheritance models, including the
recessive, additive and multiplicative models [49]. How-
ever, application of this method is beyond the scope of
the present study.
The HWD test can not only detect gene-phenotype associ-
ation, but can also reflect a genetic disease model, because
the direction of HWD statistics (Δ, F and J) varies with the
genetic model [9,35,36]. In the present study, the Δ, F and
J for SNP8 are positive, suggesting that SNP8 appears to
follow a recessive genetic disease model.
We also identified the genetic disease model for SNP8
with the best fit to the genotypic proportions observed in
patients and controls using the Mathematica Notebooks
written by Wittke-Thompson et al. [9]. Consistent with
the above inference, the "best-fit" model for SNP8 is a
recessive model. This model-fitting method can not only
identify the genetic model, but can also tell us that other
explanations for the observed HWD, including chance,
genotyping error, and/or violations of the requisite
assumptions of HWE, are less likely, if one "best-fit"
model can be identified [9]. However, it should also be
noted that just because an observed HWD is consistent
with a "best-fit" genetic model does not completely guar-
antee that errors, missing data patterns, or violations of
HWE assumptions do not generate or contribute to the
observed HWD. Actually, HWD can be attributable to aPage 9 of 13
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ther support the interpretation that non-disease factors
underlying HWD are less likely to be important in
explaining our data. We note, though, that it might take a
very large sample to fully support this conclusion.
Signal intensity, background noise, and clustering proper-
ties all play a role in the ability to assign genotypes cor-
rectly, and in determining the types of errors that occur
[52]. Genotyping error is one of the greatest concerns for
causing spurious HWD observation. First, DNA contami-
nation can result in the lack of one homozygote in the
PCR product, which leads to a deficiency of observed
homozygotes [52]. This runs counter to our data and thus
is not a possible explanation for the present study. Sec-
ond, incomplete digestion of PCR product (relevant only
when using the RFLP technique, not the TaqMan tech-
nique) or poor amplification of one of the alleles will lead
to heterozygous genotypes being read as homozygous
genotypes [53]. This kind of allele dropout can lead to an
excess of apparent homozygous genotype observations,
which does fit our data and thus needs to be considered.
Also, when genotypes are read, heterozygote genotypes
could, theoretically, be more ambiguous, and therefore
more likely to be scored as "missing," than homozygote
genotypes. To detect possible genotyping error, for family
data, we assessed the data for Mendelian consistencies by
the program PEDCHECK [54], with no non-Mendelian
inconsistencies detected. For all subjects, including family
and case-control subjects, we also replicated the geno-
types (the most accurate way to estimate genotyping error
rates), so that all genotypes were matched. Missing geno-
type data rate was not significantly different between cases
and controls. Additionally, controls were tested for HWE
and did not show the same direction of HWD statistics as
cases. Together, the evidence suggests that genotyping
error as an explanation for the observed HWD is improb-
able.
Violation of one of the other HWE assumptions (besides
selection of alleles by disease) can also cause HWD. First,
genetic drift can cause HWD. Genetic drift is the effect of
finite population size [55], such that the smaller the pop-
ulation, the more noticeable the effects of drift. All popu-
lations are finite and all genetic variation is subject to
genetic drift. In a finite population, allele frequencies fluc-
tuate by chance randomly and the fluctuation leads to
deviations from HWE (in this context, this is "sampling
error") [56]. If a population is small enough, the effects of
drift may overwhelm the other forces described below,
even selection. Our AA case sample is large enough such
that genetic drift at the disease susceptibility locus and the
marker locus can reasonably be ignored. Additionally, in
our AA control sample, which is smaller than that of cases,
HWE was not violated. Further, our AA samples are repre-
sentative of the general population [57], which supports
the interpretation that HWD in AA cases is probably not
due to a sample size issue; however, considering the small
number of homozygote observations that are critical in
driving the finding, we cannot exclude this possibility.
Second, inbreeding can cause HWD. Inbreeding is a type
of positive assortative mating which is non-random. Most
populations are geographically divided, and mating is
local, so inbreeding could be common, but to varying
extents. During inbreeding, individuals are more likely to
mate with relatives than with non-related individuals.
One common consequence of inbreeding is that the
number of heterozygotes decreases and the number of
homozygotes increases [58], which leads to HWD.
Another common consequence of inbreeding is that the
expression of deleterious recessive alleles in the popula-
tion increases, which reduces average fitness and increases
mortality ("inbreeding depression") [59], which, as
described above, can also contribute to HWD. However,
our case and control samples are ascertained as unrelated,
and we have no evidence for the existence of overlapping
generations, making inbreeding unlikely in the present
study. Third, gene flow may result in HWD. Gene flow is
the result of migration. Immigrants carrying new alleles
into the population may change the genotype frequency
distribution of that population with resulting HWD in
that generation. Contrary to selection and genetic drift,
gene flow eventually homogenizes allele frequencies
among populations. Although gene flow occurs in most
populations, its contribution to major shifts in allele fre-
quencies is usually negligible. The AA population has
been in the US for an average of about five generations
and we do not have evidence of major immigration for the
current AA generation, so gene flow resulting in HWD in
our AA sample is unlikely. Fourth, mutation may increase
the genetic variability due to genetic drift and might cause
HWD. But because change in allele frequencies induced
by mutation is so small from one generation to the next,
we can safely ignore mutation as a factor in HWD. Unless
mutation rates are abnormally high, for which we have no
evidence in the present data, the change in allele frequen-
cies is believed to be virtually nil. In conclusion, violation
of one of the above HWE assumptions causing HWD is
unlikely. However, the caution that these results are
driven primarily by a small group of subjects, and that our
conclusions would be different if just a few of them were
omitted or somehow changed diagnosis, bears repeating;
this reliance on a small number of subjects requires us to
be very tentative in our conclusions.
In addition to the factors that have been discussed, other
factors can also cause HWD. For example, population
stratification and admixture can cause HWD, as demon-
strated by Luo et al. [6]. However, we have demonstrated
that the admixture degrees in our EA and AA samples arePage 10 of 13
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the sources of HWD in our case samples. In addition, the
cases and the controls are drawn from the same popula-
tions, but the controls are in HWE for SNP8, reducing the
possibility that HWD in cases results from an effect of
admixture. Nonrandom patterns of missing data may also
generate a relatively consistent pattern of HWD (e.g., dis-
proportionate missing data in heterozygotes may lead to
a consistent pattern of HWD, with an excess of homozy-
gotes, as observed for SNP8). This possibility is common
and inevitable and thus should not be ignored. However,
our cases and controls were genotyped using same geno-
typing systems, reducing the possibility that non-random
patterns of missing data cause HWD only in cases but not
in controls. Further, if the cases or controls are old
enough, the marker can be in HWD because a specific
mortality-related allele drops out due to death associated
with advancing age [51]. However, the ages of our subjects
range from 17 to 78 years, making this explanation
unlikely. An unrecognized polymorphism in primer
sequences used in PCR may also lead to HWD, with an
excess of homozygotes, as observed for SNP8, particularly
when the primer polymorphism is in LD with the tested
marker [9]. Finally, genomic duplications or deletions (a
copy deletion could lead to hemizygosity) can also lead to
HWD [9]. We believe that these explanations are not
appropriate to explain our data in the present study, but
these factors can be excluded only through extensive
sequence analysis.
In conclusion, the presence of HWD for SNP8 suggests
that this polymorphism might be a risk locus for sub-
stance dependence in AAs, although our direct evidence
for this conclusion is weak and the false positivity cannot
completely excluded. SNP8 is located at the putative 5'
regulatory region of ADH4. It might indirectly modulate
risk for disease via LD with an unknown nearby func-
tional variant, e.g., in ABI and HapMap database, it is 2.5
kb far from and in LD with rs7434491 which could signif-
icantly alter the secondary structure of ADH4 mRNA (IDT
SciTools: http://www.idtdna.com/SciTools/Sci
Tools.aspx); it might also alter the transcription initiation
site or the capacity of transcription factors to bind to the
DNA sequence, and consequently, directly affect tran-
scription levels; it might result in mRNA instability,
altered translational efficiency, or even different protein
expression levels in different tissues. Considering our
sample size limitations, we believe that replication of
these results is critical. Nevertheless, given our findings,
we believe that it would be productive to study the effect
of this variation directly on protein expression, in order to
provide convergent validation of the findings reported
here and to elucidate the specific mechanism underlying
the association of SNP8 at ADH4 to both AD and DD.
Limitations
The limitations of the present study have been discussed
above. In summary, in the present study, because the risk
genotype is rare, some analytic approaches including the
goodness-of-fit test might not have sufficient power in
detecting associations; how conservative the correction
for multiple testing should be remains disputed; and the
function of the risk marker remains unclear. Allowing for
these limitations, the possibility that the findings are false
positive cannot be completely excluded. Future replica-
tion studies with stricter design and improved sampling
methods, and increased study power are warranted.
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